Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

Explore our recent stories to see what drives us

07 April 2021

Grünenthal’s first Environmental, Social and Governance Rating puts us ahead of our peers

Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks
As a global leader in pain research and management, we aim to create sustainable value for patients and their families, for our employees, customers and investors as well as the communities we operate in.

As a global leader in pain research and management, we aim to create sustainable value for patients and their families, for our employees, customers and investors as well as the communities we operate in. We hold ourselves to high sustainability standards and the highest ethical business practices. Our performance against environmental, social and governance (ESG) criteria has been recognized in an external rating that placed Grünenthal in the top five percent of the global pharmaceuticals subindustry that inherently features higher ESG risk. The rating agency Sustainalytics attributed a medium ESG risk to Grünenthal and acknowledged the company’s strong management of its ESG risks.

To learn more, please see our Press Release.

Share this story: